Stocks and Investing
Stocks and Investing
Tue, February 13, 2018
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Alethia Young Maintained (VRTX) at Buy with Increased Target to $196 on, Feb 13th, 2018
Alethia Young of Credit Suisse, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy with Increased Target from $195 to $196 on, Feb 13th, 2018.
Alethia has made no other calls on VRTX in the last 4 months.
There are 4 other peers that have a rating on VRTX. Out of the 4 peers that are also analyzing VRTX, 0 agree with Alethia's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with Alethia
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $200 on, Friday, February 2nd, 2018
- Ying Huang of "B of A Securities" Maintained at Strong Buy with Increased Target to $197 on, Thursday, February 1st, 2018
- Do Kim of "BMO Capital" Maintained at Buy with Increased Target to $191 on, Thursday, February 1st, 2018
- Geoff Meacham of "Barclays" Maintained at Buy with Increased Target to $200 on, Thursday, February 1st, 2018